iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Glenmark Pharma Surges 10% as Management Forecasts Improved Margins and Product Launches

16 Feb 2024 , 03:18 PM

Glenmark Pharma shares surged around 10% for the second consecutive session on February 16. At the time of writing, the stock was trading at ₹873, marking a 7.74% increase on the NSE. The positive momentum follows the company's Q3 earnings report, which revealed a net loss of ₹330.8 Crore for the December quarter.

The loss was attributed to various one-off expenses, including a one-time impact on Glenmark's India business, a forex loss of ₹16.2 Crore, hyperinflationary impact of ₹48 Crore in Argentina, and exceptional items related to remediation costs of ₹76.7 Crore for manufacturing sites in India and the US.

Despite the Q3 challenges, the management remains optimistic about the future, hinting at better times for the drug manufacturer. The management anticipates an improvement in EBITDA and consistent margin improvement in the coming quarters.

Bullishness is attributed to the production from the newly acquired Monroe site and the upcoming commercialization of two products from this facility.

Glenmark plans to launch two nasal sprays in FY25, with sales expectations of ₹8 Crore from the nasal spray Rylatris, a significant product for the company.

Ryaltris is considered a major driver for the company's margins, and respiratory and injectables are expected to be major contributors in FY25.

Glenmark aims to turn cash positive by the end of the current fiscal year and expects ₹5,000 Crore from its stake in the subsidiary, Glenmark Life Sciences.

For feedback and suggestions, write to us at editorial@iifl.com


Related Tags

  • Glenmark Pharma
  • news
sidebar mobile


12 Apr 2024   |   01:37 PM
12 Apr 2024   |   10:20 AM
12 Apr 2024   |   10:16 AM
Read More

Most Read News

12 Apr 2024   |   08:25 PM
12 Apr 2024   |   08:14 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:08 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.


Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp